CrownBio expands humanised models for targeted immunotherapy

The humanised model expansion programme will begin with PD-1, CTLA-4 and CD137 models

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has extended its existing portfolio of humanised drug target models (HuGEMM) to its San Diego facility.

This service offering expansion to the San Diego site will begin with humanised PD-1, PD-L1, CTLA-4, OX40, CD137, PD-1/PD-L1, and PD-1/CTLA-4 targets. Additional HuGEMM models will follow later this year to help advance development of immuno-oncology (I/O) drugs.

The expansion of this novel translational platform to CrownBio's San Diego laboratory makes it more accessible to both the North American and worldwide research community.

CrownBio provides the biopharmaceutical research community with innovative preclinical platforms to evaluate human-specific immunotherapies in vivo, while shortening experimental timelines and mitigating costs.

The HuGEMM portfolio helps achieve this by featuring fully functional murine immunity with a humanised drug target that can be used in conjunction with syngeneic/homograft mouse tumours.

"Our HuGEMM portfolio is uniquely positioned to expedite study timelines, save researcher's money and deliver valuable insights about targeted immunotherapies," said Dr Henry Li, Senior VP of Global Scientific Research and Innovation.

"We are very excited about continuing to grow this platform and to make it more available to scientists globally via the expansion of our San Diego laboratory."

Companies